CAS 1138549-36-6 appears in our catalog under these names: CX–5461, CX-5461/ 99.25% (existing batch purity), CX 5461, CX-5461 98%, 2-(Hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-N-[(5-methyl-2-pyrazinyl)methyl]-5-oxo-5H-Benzothiazolo[3,2-a][1,8]naphthyridine-6-carboxamide, 98%, 98%. Offered by: GLPBio, TargetMol, Biosynth, Ambeed, Chemat. Available pack sizes: 10mg, 5mg, 50mg, 1mg, 2mg, 25mg, 100mg, 500mg.
CX-5461 is an organic heterotetracyclic compound that is 5-oxo-5H-[1,3]benzothiazolo[3,2-a][1,8]naphthyridine-6-carboxylic acid substituted by a 4-methyl-1,4-diazepan-1-yl group at position 2 and in which the carboxy group at position 6 is substituted by a [(5-methylpyrazin-2-yl)methyl]nitrilo group. An inhibitor of ribosomal RNA (rRNA) synthesis which specifically inhibits RNA polymerase I-driven transcription of rRNA in several cancer cell lines. It is currently in phase I/II clinical trials for advanced hematologic malignancies and triple-negative breast cancer with BRCA1/2 mutation. It has a role as an antineoplastic agent, an EC 2.7.7.6 (RNA polymerase) inhibitor and an apoptosis inducer. It is a secondary carboxamide, an organic heterotetracyclic compound, a member of pyrazines, a diazepine and a naphthyridine derivative.
Source: ChEBI
| Molecular formula | C27H27N7O2S |
|---|---|
| Molecular weight | 513.6 g/mol |
| IUPAC name | 2-(4-methyl-1,4-diazepan-1-yl)-N-[(5-methylpyrazin-2-yl)methyl]-5-oxo-[1,3]benzothiazolo[3,2-a][1,8]naphthyridine-6-carboxamide |
| InChIKey | XGPBJCHFROADCK-UHFFFAOYSA-N |
| SMILES | CC1=CN=C(C=N1)CNC(=O)C2=C3N(C4=CC=CC=C4S3)C5=C(C2=O)C=CC(=N5)N6CCCN(CC6)C |
Computed by PubChem (NCBI)